Derma Sciences to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17

PRINCETON, N.J.--()--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that Edward J. Quilty, president and chief executive officer, will present to investors as part of the Lippert/Heilshorn & Associates Life Sciences & Medical Technologies On-line Forum on Thursday, February 17, 2011 at 1:30 p.m. Eastern. The presentation will provide a corporate overview and a discussion of the Company’s growth strategy.

Interested parties can access the audio webcast with slide presentation at www.dermasciences.com, or from the PrecisionIR event site: http://www.investorcalendar.com/CEPage.asp?ID=163511.

An archived presentation will be available for 30 days.

About Derma Sciences, Inc.

Derma Sciences is a medical technology company focused on three segments of the wound care marketplace, traditional dressings, advanced wound care dressings, and pharmaceutical wound care products. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for infection prevention. Derma Sciences has successfully completed the treatment phase of a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, a novel pharmaceutical drug under development for accelerated wound healing and scar reduction. For more information please visit www.dermasciences.com.

Forward-Looking Statements

Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's filings with the U.S. Securities and Exchange Commission.

Contacts

Derma Sciences, Inc.
Barry Wolfenson
Executive Vice President, Global Marketing and Business Development
609-514-4744
bwolfenson@dermasciences.com
or
Lippert/Heilshorn & Associates
Investors
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
or
Bruce Voss
310-691-7100
bvoss@lhai.com
or
Media
Megan Rusnack
212-838-3777
mrusnack@lhai.com

Contacts

Derma Sciences, Inc.
Barry Wolfenson
Executive Vice President, Global Marketing and Business Development
609-514-4744
bwolfenson@dermasciences.com
or
Lippert/Heilshorn & Associates
Investors
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
or
Bruce Voss
310-691-7100
bvoss@lhai.com
or
Media
Megan Rusnack
212-838-3777
mrusnack@lhai.com